KLOW (BPC-157 + TB-500 + KPV + GHK-Cu)

Overview

What is KLOW (BPC-157 + TB-500 + KPV + GHK-Cu)?

KLOW is a four peptide blend adding KPV, a melanocortin derived tripeptide with anti-inflammatory activity, to the three peptides in GLOW. It is used in regenerative and healing protocols, and the combination itself has no published clinical trial.

• Tissue Repair
• Anti-Inflammatory
• Gut Health
• Skin Rejuvenation

What the research reports

Reported research benefits

Outcomes described across the published literature and ongoing study. Read each as research context rather than a promised personal result.

1. 01

   Added inflammatory control

   KPV contributes anti-inflammatory activity through a route largely independent of the melanocortin receptors, complementing the three repair peptides in the stack.

2. 02

   Four pathway repair coverage

   Brings together collagen signalling, angiogenesis, actin regulation and inflammatory suppression within a single research protocol. Reported in research settings.

3. 03

   Gut inflammation focus work

   KPV has published animal work in colitis models, which adds a gut dimension alongside the BPC-157 component. Noted across the published research record.

4. 04

   Skin and wound application

   The GHK-Cu and KPV components both feature in skin research, broadening the blend beyond musculoskeletal recovery. Noted across the published research record.

5. 05

   Component level study support

   Each peptide carries its own preclinical record, so the blend inherits the evidence of its parts rather than adding its own. Reported in research settings.

Dosage and protocol

Dosage and protocol reference

Blend protocols combine BPC-157 at 250 to 500 mcg, TB-500 at 2 to 5 mg weekly, GHK-Cu at 1 to 2 mg and KPV at 200 to 500 mcg. Figures describe study protocols, not a personal regimen.

Route

Subcutaneous injection

Example range

Per component dose

Frequency

Daily to twice weekly

Timing

Dose on shortest component schedule. Label vials clearly to avoid mix.

Clinical evidence

Clinical evidence and study base

The published record, labeled by strength so you can see what is settled and what is still emerging.

Interactions

How it pairs with other peptides

GLOW blend

KLOW is GLOW with KPV added, so running both together duplicates three of the four components.

Ipamorelin

No known negative interaction. The growth hormone axis sits apart from these repair mechanisms.

Immunosuppressants

KPV modulates inflammatory signalling, which may matter alongside therapies that suppress immunity.

Copper supplements

The GHK-Cu component already delivers copper, so additional sources add to total exposure.